Caribou Biosciences Limited Use Label License: Human Cell Research Use Only

Notice End Users: This product is purchased from or otherwise provided by The Jackson Laboratory subject to a “Limited Use Label License” conveying to the end-user (“End User”) of the product a limited, non-transferable right to use the product, solely as provided to End User, together with (i) progeny or derivatives of the product generated by the End User (including, but not limited to, cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including, but not limited to, cells) (collectively, the product, as provided, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the End User.

The End User cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes or reproductive cells; and/or (h) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). Notwithstanding the foregoing, End User may transfer Material to a third party under a contractual obligation to perform research for the sole benefit of the End User, or to a third party that is a nonprofit performing collaborative research with the End User; provided however that any such transfer of Material to a third party is accompanied by this Limited Use Label License.

It is the End User’s responsibility to use the Material in accordance with all applicable laws and regulations.

For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing.

Exhibit A: Licensed Patent Rights

Modified Cascade Ribonucleoproteins and Uses Thereof
Country	Application number/ Patent number	Filing date/ Grant date	Status

US	14/240,735	02/24/2014	Abandoned
US	14/326,099	07/08/2014	Abandoned
US	14/997,467	01/15/2016	Pending
US	14/997,474	01/15/2016	Pending
AU	2012360975	12/21/2012	Pending
BR	112014016228-0	12/21/2012	Pending
CA	2,862,018	12/21/2012	Pending
CN	201280071058.4	12/21/2012	Abandoned
CN	201610081216.4	12/21/2012	Pending
DE	212012000234.0 212012000234.0	12/21/2012 08/07/2014 (exp. 12/21/2022)	Granted
EP	12812999.6	12/21/2012	Abandoned
EP	16169431.0	12/21/2012	Pending
GB	1411878.0 2512246	12/21/2012 07/20/2016 (exp. 12/21/2032)	Granted
IL	233399	12/21/2012	Pending
IN	5937/DELNP/2014	12/21/2012	Pending
JP	2014-549450	12/21/2012	Pending
KR	2014-7021336	12/21/2012	Pending
MX	MX/a/2014/007910	12/21/2012	Pending
RU	2014127702	12/21/2012	Pending
SG	11201403713Q	12/21/2012	Pending
TH	1401003836	12/21/2012	Pending
WO	PCT/EP2012/076674	12/21/2012	National phase
GB	1122458.1	12/30/2011	Withdrawn

Compositions and Methods of Nucleic Acid-Targeting Nucleic Acids
Country	Application number/ Patent number	Filing date/ Grant date	Status

US	14/206,319	03/12/2014	Pending
US	14/416,338 US 9,260,752	01/22/2015 02/16/2016 (exp. 03/12/2034)	Granted
US	14/749,594	06/24/2015	Pending
US	14/749,599	06/24/2015	Pending
US	14/751,055 US 9,410,198	06/25/2015 08/09/2016 (exp. 03/12/2034)	Granted
US	14/751,058	06/25/2015	Pending
US	14/751,070	06/25/2015	Pending
US	14/751,088	06/25/2015	Pending
US	14/977,514	12/21/2015	Pending
US	15/159,619	05/19/2016	Pending
US	15/159,776	05/19/2016	Pending
US	15/202,518	07/05/2016	Pending
AU	2014235794	03/12/2014	Pending
AU	2015101418 2015101418	03/12/2014 10/29/2015 (exp. 03/12/2022)	Granted
BR	112015022061-4	03/12/2014	Pending
CA	2,905,432	03/12/2014	Pending
CN	201480028062.1	03/12/2014	Pending
EP	14771135.2	03/12/2014	Pending
GB	1517172.1	03/12/2014	Pending
HK	16100993.9	03/12/2014	Pending
IL	241563	03/12/2014	Pending
IN	5749/CHENP/2015	03/12/2014	Pending
JP	2016-501357	03/12/2014	Pending
KR	2015-7028606	03/12/2014	Pending
MX	MX/a/2015/013057	03/12/2014	Pending
NZ	712727	03/12/2014	Pending
RU	2015140276	03/12/2014	Pending
SG	11201507378U	03/12/2014	Pending
ZA	2015/07006	03/12/2014	Pending
WO	PCT/US2014/023828	03/12/2014	National phase
US	61/781,598	03/14/2013	Expired
US	61/818,382	05/01/2013	Expired
US	61/818,386	05/01/2013	Expired
US	61/822,002	05/10/2013	Expired
US	61/832,690	06/07/2013	Expired
US	61/845,714	07/12/2013	Expired
US	61/858,767	07/26/2013	Expired
US	61/859,661	07/29/2013	Expired
US	61/865,743	08/14/2013	Expired
US	61/883,804	09/27/2013	Expired
US	61/899,712	11/04/2013	Expired
US	61/900,311	11/05/2013	Expired
US	61/902,723	11/11/2013	Expired
US	61/903,232	11/12/2013	Expired
US	61/906,211	11/19/2013	Expired
US	61/906,335	11/19/2013	Expired
US	61/907,216	11/21/2013	Expired
US	61/907,777	11/22/2013	Expired

RNA Modification to Engineer Cas9 Activity
Country	Application number/ Patent number	Filing date/ Grant date	Status

US	14/791,195	07/02/2015	Pending
US	14/791,200	07/02/2015	Pending
WO	PCT/2015/037546	06/24/2015	Pending
US	62/017,113	06/25/2014	Expired
US	62/065,515	10/17/2014	Expired
US	62/088,277	12/05/2014	Expired

Methods for Increasing Cas9-Mediated Engineering Efficiency
Country	Application number/ Patent number	Filing date/ Grant date	Status

US	14/836,753	08/26/2015	Pending
WO	PCT/US2015/047046	08/26/2015	Pending
US	62/042,358	08/27/2014	Expired
US	62/047,495	09/08/2014	Expired

RNA-Directed DNA Cleavage by the Cas9-crRNA Complex (Owner: Vilnius University) Amended and Restated Collaboration and License Agreement, by and between Pioneer Hi-Bred International, Inc. and Caribou Biosciences, Inc., dated July 13, 2015
Country	Application number/ Patent number	Filing date/ Grant date	Status

US	14/385,241	09/15/2014	Pending
US	14/385,857	09/17/2014	Pending
US	14/683,443	04/10/2015	Pending
US	14/743,764	06/18/2015	Pending
BR	112014023353-5	03/20/2013	Pending
CA	2,867,849	03/20/2013	Pending
CN	201380023255.3	03/20/2013	Pending
EA	201491728	03/20/2013	Pending
EP	13715080.1	03/20/2013	Pending
HK	2015107124	03/20/2013	Pending
IN	7846/DELNP/2014	03/20/2013	Pending
JP	2015-5011880	03/20/2013	Pending
MX	MX/a/2014/011279	03/20/2013	Pending
ZA	2014/06897 2014/06897	03/20/2013 12/23/2015 (exp. 03/20/2033)	Granted
WO	PCT/LT2013/000006	03/15/2013	National phase
WO	PCT/US2013/033106	03/20/2013	National phase
US	61/613,373	03/20/2012	Expired
US	61/625,420	04/17/2012	Expired

Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription (Owners: The Regents of the University of California, University of Vienna, and Emmanuelle Charpentier) Exclusive License Agreement, by and among Caribou Biosciences, Inc., University of Vienna, and The Regents of the University of California, dated April 16, 2013
Country	Application number/ Patent number	Filing date/ Grant date	Status

US	13/842,859	03/15/2013	Interference No. 106,048 pending
US	14/403,475	11/24/2014	Abandoned
US	14/685,502	04/13/2015	Pending
US	14/685,504	04/13/2015	Pending
US	14/685,513	04/13/2015	Abandoned
US	14/685,514	04/13/2015	Abandoned
US	14/685,516	04/13/2015	Abandoned
US	14/942,782	11/16/2015	Pending
US	15/090,511	04/04/2016	Pending
US	15/138,604	04/26/2016	Pending
AU	2013266968	03/15/2013	Pending
BR	1120140299441-0	03/15/2013	Pending
CA	2,872,241	03/15/2013	Pending
CN	201380038920.6	03/15/2013	Pending
DE	202013012240 202013012240	03/15/2013 02/02/2016 (exp. 03/31/2023)	Granted
DE	202013012241 202013012241	03/15/2013 01/18/2016 (exp. 03/31/2023)	Granted
DE	202013012242 202013012242	03/15/2013 02/02/2016 (exp. 03/31/2023)	Granted
EA	201401319	03/15/2013	Pending
EP	13793997.1	03/15/2013	Pending
GB	1420270.9 GB2518764	03/15/2013 03/02/2016 (exp. 03/15/2033)	Granted
GB	1601071.2	03/15/2013	Pending
HK (EP)	15104473.1	03/15/2013	Pending
HK (CN)	15112610.8	03/15/2013	Pending
HK (GB)	15106335.4	03/15/2013	Pending
IL	235461	03/15/2013	Pending
IN	2995/KOLNP/2014	03/15/2013	Pending
JP	2015-514015	03/15/2013	Pending
KR	2014-7036096	03/15/2013	Pending
MX	MX/a/2014/014477	03/15/2013	Pending
SG	11201407702X	03/15/2013	Pending
ZA	2014/07881	03/15/2013	Pending
WO	PCT/US2013/032589	03/15/2013	National phase
US	61/652,086	05/25/2012	Expired
US	61/716,256	10/19/2012	Expired
US	61/757,640	01/28/2013	Expired
US	61/765,576	02/15/2013	Expired